{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:47:33Z","timestamp":1793746053769,"version":"4.6.1"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T00:00:00Z","timestamp":1738195200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.vaccine.2025.126829","type":"journal-article","created":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T12:23:04Z","timestamp":1738758184000},"page":"126829","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"special_numbering":"C","title":["Advancing local manufacturing capacities for vaccines within Africa \u2013 Opportunities, priorities and challenges"],"prefix":"10.1016","volume":"50","author":[{"given":"Joachim","family":"Doua","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicaise","family":"Ndembi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen","family":"Auerbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Kaseya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alimuddin","family":"Zumla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.vaccine.2025.126829_bb0005","doi-asserted-by":"crossref","first-page":"2020529","DOI":"10.1080\/21645515.2021.2020529","article-title":"Capacity building for vaccine manufacturing across developing countries: the way forward","volume":"18","author":"Kumraj","year":"2022","journal-title":"Hum Vaccin Immunother"},{"issue":"10159","key":"10.1016\/j.vaccine.2025.126829_bb0010","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1016\/S0140-6736(18)32335-3","article-title":"Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the global burden of disease study 2017","volume":"392","author":"DALYs","year":"2018","journal-title":"Lancet"},{"issue":"10441","key":"10.1016\/j.vaccine.2025.126829_bb0015","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1016\/S0140-6736(24)00850-X","article-title":"Contribution of vaccination to improved survival and health: modelling 50 years of the expanded Programme on immunization","volume":"403","author":"Shattock","year":"2024","journal-title":"Lancet"},{"issue":"43","key":"10.1016\/j.vaccine.2025.126829_bb0020","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.15585\/mmwr.mm7243a1","article-title":"Routine vaccination coverage - worldwide, 2022","volume":"72","author":"Kaur","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"27","key":"10.1016\/j.vaccine.2025.126829_bb0025","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1016\/j.vaccine.2023.05.009","article-title":"Building global vaccine manufacturing capacity: spotlight on Africa","volume":"41","author":"Rubin Thompson","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.126829_bb0030","author":"WelcomeTrust"},{"key":"10.1016\/j.vaccine.2025.126829_bb0035","author":"AfricaCDC(a)"},{"issue":"12","key":"10.1016\/j.vaccine.2025.126829_bb0040","doi-asserted-by":"crossref","first-page":"910","DOI":"10.2471\/BLT.21.287381","article-title":"Addressing production gaps for vaccines in African countries","volume":"99","author":"Ekstrom","year":"2021","journal-title":"Bull World Health Organ"},{"issue":"1","key":"10.1016\/j.vaccine.2025.126829_bb0045","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s41182-023-00564-2","article-title":"Vaccine inequity: a threat to Africa\u2019s recovery from COVID-19","volume":"51","author":"Wei","year":"2023","journal-title":"Trop Med Health"},{"issue":"9","key":"10.1016\/j.vaccine.2025.126829_bb0050","first-page":"2861","article-title":"Pharmaceutical manufacturing plan for Africa is critical for pandemic preparedness, prevention and response","volume":"14","author":"Mynhardt","year":"2023","journal-title":"J Public Health Afr"},{"issue":"10404","key":"10.1016\/j.vaccine.2025.126829_bb0055","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0140-6736(23)01414-9","article-title":"Bold moves for vaccine manufacturing equity","volume":"402","author":"Aars","year":"2023","journal-title":"Lancet"},{"issue":"10336","key":"10.1016\/j.vaccine.2025.126829_bb0060","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0140-6736(22)00775-9","article-title":"Africa CDC warns COVID-19 vaccine production could cease","volume":"399","author":"Adepoju","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2025.126829_bb0065","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/d41586-022-00335-9","volume":"602","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2025.126829_bb0070","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3389\/fpubh.2019.00056","article-title":"Vaccine production in Africa: a feasible business model for capacity building and sustainable new vaccine introduction","volume":"7","author":"Makenga","year":"2019","journal-title":"Front Public Health"},{"key":"10.1016\/j.vaccine.2025.126829_bb0075","unstructured":"Dutton J. First African-made mRNA vaccine, a test platform for the future. Nature Africa 2022. https:\/\/www.nature.com\/articles\/d44148-022-001513#:~:text=Afrigen%20Biologics%20and%20Vaccines%20has,company%2C%20will%20industrialise%20the%20vaccine."},{"key":"10.1016\/j.vaccine.2025.126829_bb0080","author":"GAVITheVaccineAlliance"},{"key":"10.1016\/j.vaccine.2025.126829_bb0085","author":"WorldEconomicForum"},{"issue":"4","key":"10.1016\/j.vaccine.2025.126829_bb0090","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/tmi.13865","article-title":"Vaccine development for bacterial pathogens: advances, challenges and prospects","volume":"28","author":"Mba","year":"2023","journal-title":"Trop Med Int Health"},{"key":"10.1016\/j.vaccine.2025.126829_bb0095","author":"AfricaCDC(b)"},{"key":"10.1016\/j.vaccine.2025.126829_bb0100","author":"AfricaCDC(c)"},{"key":"10.1016\/j.vaccine.2025.126829_bb0105","author":"AFRIGEN"},{"key":"10.1016\/j.vaccine.2025.126829_bb0110","author":"ASPEN"},{"key":"10.1016\/j.vaccine.2025.126829_bb0115","series-title":"BIOVAC","year":"2024"},{"key":"10.1016\/j.vaccine.2025.126829_bb0120","series-title":"Vaccines and diagnostics manufacturing","author":"Dakar","year":"2023"},{"issue":"7971","key":"10.1016\/j.vaccine.2025.126829_bb0125","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/d41586-023-02316-y","article-title":"Africa: a new dawn for local vaccine manufacture","volume":"619","author":"Ndembi","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2025.126829_bb0130","author":"InstitutPasteurDakar"},{"key":"10.1016\/j.vaccine.2025.126829_bb0135","author":"CHAI"},{"issue":"33","key":"10.1016\/j.vaccine.2025.126829_bb0140","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1016\/j.vaccine.2017.06.003","article-title":"The complexity and cost of vaccine manufacturing - an overview","volume":"35","author":"Plotkin","year":"2017","journal-title":"Vaccine"},{"issue":"52","key":"10.1016\/j.vaccine.2025.126829_bb0145","doi-asserted-by":"crossref","first-page":"6655","DOI":"10.1016\/j.vaccine.2016.10.016","article-title":"Vaccine development: from concept to early clinical testing","volume":"34","author":"Cunningham","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.126829_bb0150","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.517290","article-title":"Challenges of developing novel vaccines with particular Global Health importance","volume":"11","author":"Heaton","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2025.126829_bb0155","author":"InstitutPasteur"},{"issue":"2","key":"10.1016\/j.vaccine.2025.126829_bb0160","first-page":"83","article-title":"Medicines regulatory science expertise in Africa: workforce capacity development and harmonisation activities towards the establishment of the African medicines agency","volume":"36","author":"Ncube","year":"2022","journal-title":"Pharmaceut Med"},{"issue":"5","key":"10.1016\/j.vaccine.2025.126829_bb0165","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/hcs2.117","article-title":"3rd. The African medicines agency and medicines regulation: Progress, challenges, and recommendations","volume":"3","author":"Abdulwahab","year":"2024","journal-title":"Health Care Sci"},{"issue":"33","key":"10.1016\/j.vaccine.2025.126829_bb0170","doi-asserted-by":"crossref","first-page":"4897","DOI":"10.1016\/j.vaccine.2012.05.058","article-title":"Development and technology transfer of Haemophilus influenzae type b conjugate vaccines for developing countries","volume":"30","author":"Beurret","year":"2012","journal-title":"Vaccine"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2025.126829_bb0175","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1093\/cid\/ciy884","article-title":"Overview of the typhoid conjugate vaccine pipeline: current status and future plans","volume":"68","author":"Sahastrabuddhe","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2025.126829_bb0180","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.3389\/fimmu.2018.01068","article-title":"Changing priorities in vaccinology: antibiotic resistance moving to the top","volume":"9","author":"Tagliabue","year":"2018","journal-title":"Front Immunol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25001264?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25001264?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T11:29:39Z","timestamp":1741778979000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X25001264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":36,"alternative-id":["S0264410X25001264"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.126829","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advancing local manufacturing capacities for vaccines within Africa \u2013 Opportunities, priorities and challenges","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.126829","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"126829"}}